Updated:
BioAdaptives
BioAdaptives is an OTC-traded micro-cap operated by James E. Roberts since 2014, selling dietary supplements and wellness devices.
BioAdaptives
BioAdaptives, Inc. was incorporated in Nevada in 2014 with James E. Roberts at the helm as CEO and director. The firm operates as a shell-like publicly traded company on the OTC Markets, focusing on what it describes as ingestible and topical wellness products and biofeedback devices. Unlike a single-family office or institutional allocator, BioAdaptives functions as a thinly capitalized operating business, selling directly to consumers and generating minimal top-line revenue. The company's strategy centers around direct-to-consumer sales of supplements branded under lines like 'Primum' and electronic devices that it claims modulate cellular frequencies to improve health. The company has cycled through strategic pivots, at times highlighting pet supplements and at-home food cultivation systems alongside human wellness products. Published financials in public filings show annual revenues that rarely exceed a few hundred thousand dollars, with operations funded through convertible note issuances and equity sales rather than asset-management fees or carried interest. The firm maintains a skeletal corporate footprint with headquarters in Las Vegas, Nevada, and no disclosed count of professionals. There are no known adjacent philanthropic vehicles, co-investment clubs, or institutional limited partners. In September 2023, the company amended its authorized share count in a filing with the state of Nevada, a corporate action typical of micro-cap issuers managing dilution and convertible instruments (per the firm's official communications and public records). What structurally distinguishes BioAdaptives is its posture as a publicly traded micro-cap with no institutional backing, no diversified asset base, and no evidence of external capital allocation. It is an operating company, not a fund manager. The governance is concentrated in a single named executive, with succession and oversight risk governed by OTC Markets disclosure requirements rather than the fiduciary standards applied to registered investment advisors or family offices.
General information
Firm type
Asset Manager
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Las Vegas
Corporate office
Las Vegas, NV, United States
Principals
James E. Roberts
Chief Executive Officer
Sector focus
Frequently asked questions
Is BioAdaptives structured as a family office, an asset manager, or an operating company?
BioAdaptives is an operating company, not a family office or asset manager. It is a publicly traded micro-cap on the OTC Markets that generates revenue by selling dietary supplements and biofeedback devices directly to consumers. It does not manage third-party capital or a family pool of assets, and there are no known underlying wealth sources driving its balance sheet. The confusion likely arises from misclassification in commercial databases.
What specific products does BioAdaptives sell?
The company markets ingestible supplements under the 'Primum' brand and wellness devices it claims use bioenergetic technologies to influence cellular health. Product lines have historically included items for both humans and pets, along with ventures into home food-cultivation equipment. Revenue from these lines has been minimal and is disclosed in quarterly OTC filings.
Who controls investment and strategic decisions at BioAdaptives?
James E. Roberts serves as the Chief Executive Officer and a director, concentrating operational and strategic control. The firm has not disclosed an independent investment committee, a chief investment officer, or any board-level governance body beyond what is required by OTC Markets regulation. All material corporate actions, including capital-structure amendments, flow through executive management.
Does BioAdaptives allocate capital to external funds or direct investments?
No. BioAdaptives does not operate as a fund-of-funds, venture capital investor, or co-investment vehicle. Its use of cash is limited to operating expenses, inventory procurement, and servicing convertible debt. Public financials show no evidence of a limited-partner program, institutional fund commitments, or a portfolio of investee companies.
What is the firm's revenue scale and financial condition?
Annual revenue has historically been below $1 million, with the company relying on equity financings and convertible note issuances to maintain operations. This is typical of a pre-revenue or minimally-revenue public micro-cap. The firm has no disclosed assets under management, no fee-based income stream, and no institutional capital backing.
Where does the company's public listing trade, and what is its regulatory posture?
BioAdaptives trades on the OTC Markets under the ticker BDPT. OTC Markets is an alternative trading venue with lighter disclosure requirements than NASDAQ or the NYSE. The firm is registered in Nevada and files periodic disclosures with OTC Markets Group, but is not subject to the full SEC reporting regime applied to exchange-listed companies.
Has BioAdaptives ever been structured differently in the past?
Public records indicate the company was incorporated in its current form in 2014 and has consistently operated as a consumer-focused wellness entity. There have been periodic shifts in product emphasis, including a pivot toward pet-focused supplements and vertical agriculture, but the corporate structure as an OTC-traded operating company has remained unchanged since inception.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: